4 views left Get unlimited views with a free account

Subscribe to GlobalData Explorer

Explore the latest trends and actionable insights on the Turner Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Turner Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 9 ongoing clinical trials involving Turner Syndrome
Of the 9 trials,5 trials are in Phase IV
Furthermore, 3 trials are in Phase 0

Number of ongoing Clinical Trials (for drugs) involving Turner Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Turner Syndrome, an Infectious Disease condition. The largest number of ongoing clinical trials for Turner Syndrome is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Turner Syndrome-related drug trials.

Guangzhou Women and Children's Medical Center : The leading ongoing Turner Syndrome related clinical trial sponsor

Guangzhou Women and Children's Medical Center is the top sponsor for Turner Syndrome-related ongoing clinical trials.

Aarhus University Hospital, Lumos Pharma Inc, Dong-A Socio Holdings Co Ltd and JCR Pharmaceuticals Co Ltd are among other notable clinical trial sponsors involved in Turner Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Turner Syndrome

Somatropin (Norditropin, Norditropin Simplexx, Norditropin Flexpro, Norditropin Penset/, Nanormon, Norditropin Nordilet, Norditropin Nordiflex, Norditropin S), Somatropin (Genotropin, Genotonorm/Genotropin MiniQuick/ Genotropin KabiQuick) and Somatropin recombinant (Humatrope, Umatrope) are among the key marketed drugs involving Turner Syndrome.

Somatropin (Norditropin, Norditropin Simplexx, Norditropin Flexpro, Norditropin Penset/, Nanormon, Norditropin Nordilet, Norditropin Nordiflex, Norditropin S) is a recombinant polypeptide human growth hormone of recombinant DNA origin. It functions via Growth Hormone Receptor (Somatotropin Receptor or GHR) Agonist mechanism of action. Somatropin is formulated as injectable solution and injectable powder for solution for subcutaneous route of administration. Somatropin was first approved in 1979 and is marketed globally in the US, UK, China, Japan, Germany, and France by Novo Nordisk Inc and its subsidiaries.

Somatropin (Genotropin, Genotonorm/Genotropin MiniQuick/ Genotropin KabiQuick) is a recombinant polypeptide human growth hormone of recombinant DNA origin. It functions via Growth Hormone Receptor (Somatotropin Receptor or GHR) Agonist mechanism of action. Somatropin is formulated as injection sterile lyophilized powder intended for subcutaneous administration. Somatropin was first approved in 1987 and is marketed globally in the US, UK, France, Germany, China and Japan by Pfizer Inc and its subsidiaries.

Explore the latest trends and actionable insights on the Turner Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Turner Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store